Development and targeted use of nilotinib in chronic myeloid leukemia

Carmen Fava
Hagop Kantarjian
Jorge Cortes
Elias Jabbour

Department of Leukemia,
The University of Texas MD Anderson Cancer Center,
Houston, Texas, USA

Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.

Keywords: nilotinib, imatinib-resistance, imatinib-intolerance, CML

Ph-positive chronic myeloid leukemia

Chronic myeloid leukaemia (CML) is a rare disease. Although its incidence is low, the prevalence of CML is increasing. In the US, the annual incidence of CML is 1.5 cases/100,000 adults, accounting for 15% of all of the forms of diagnosed leukemia (Ries et al 2004).

CML is one of the most extensively studied and, arguably, best understood neoplasms. CML is the first malignant disease for which a direct gene link has been found and there has been much recent progress in the understanding of the biology of the disease (Faderl et al 1999; Barnes and Melo 2002; Litzow 2006; Quintas-Cardama and Cortes 2006). The cytogenetic hallmark of CML is the Philadelphia chromosome (Ph), a reciprocal translocation between chromosomes 9 and 22 (t(9; 22)(q34; q11)). This translocation is present in 95% of patients with CML (Rowley 1973).

The conjugation of the breakpoint cluster region gene on chromosome 22 and the Abelson (Abl) kinase gene on chromosome 9 is a product of unfaithful repair of 2 DNA double-strand breaks in genes encoding BCR and ABL that creates the chimeric BCR-ABL oncogene, which codes for a deregulated tyrosine kinase (Koptyra et al 2006). The 210 kDa Bcr-Abl protein is expressed in CML patients, whereas a 190 kDa Bcr-Abl protein, resulting from an alternative breakpoint in the BCR gene, is expressed in Ph+ acute lymphoblastic leukaemia (ALL) patients (Chan et al 1987).

Bcr-Abl displays transforming activity owing to its constitutive kinase activity, which results in multiple signal transduction pathways, including Ras/Raf/mitogen-activated protein kinase (MAPK), phosphatidylinositol 3 kinase, STAT5/Janus kinase, and Myc, leading to uncontrolled cell proliferation and reduced apoptosis and...
resulting in the malignant expansion of pluripotent stem cells in bone marrow (Bhatia et al 2003; Hu et al 2004).

The Bcr-Abl kinase itself enhances genomic instability leading to accumulation of secondary genetic errors, which may be responsible for resistance to small molecule drugs, such as imatinib, and transformation to advanced phases (Koptyra et al 2006).

CML normally progresses through 3 clinically recognized phases. Approximately 90% of patients are diagnosed during the typically indolent chronic phase (CP), which is followed by an accelerated phase (AP) and a terminal blastic phase (BP).

The criteria for passage into CML-AP and CML-BP are defined hematologically on the basis of blast cell and progenitor cell counts. CML-AP persists for several months before the transition into CML-BP, typically defined as 30% blasts in the peripheral blood or bone marrow. Median survival in CML-BP is 3 to 6 months. CML-BP can manifest as myeloid, lymphoid, or undifferentiated phenotypes. Although progression through all stages is most common, 20% to 25% of patients progress directly from CP to BP. The time course for progression can also be extremely varied.

The mechanisms behind CML disease progression are not fully understood. As patients progress through the different phases, cytogenetic abnormalities may be detected in addition to the Ph chromosome (termed clonal evolution). Besides the propensity of the Ph-positive clone to acquire additional genetic changes, the BCR-ABL gene itself may acquire mutations that allow an already genetically unstable phenotype to further changes. Furthermore mutations and deletions in other specific genes may also occur (eg, p53, p16/INK4a, and RB). Increasing evidence suggests that Src family kinases may be involved in CML disease progression through the induction of cytokine independence and apoptotic protection (Lionberger et al 2000; Donato et al 2003; Dai et al 2004).

One of the major differences between the CP and BP of CML is their differential responsiveness to antileukemia treatment including tyrosine kinase inhibitors. Whereas most patients in CP achieve sustained responses, responses in patients with BP are usually transient.

In selected patients, allogeneic stem cell transplantation (ASCT), can be curative (Goldman and Melo 2003). Many patients, however, are not candidates for ASCT because of advanced age, the extent and/or duration of disease, or lack of availability of well-matched donors. The curative ability of ASCT resides, in part, in a direct graft-versus-leukemia effect that has permitted reductions in the intensity of ablative chemotherapy and/or substitution of immunosuppressive agents, with consequent extension of this treatment to patients previously not considered candidates for ASCT. Graft-versus-host disease and opportunistic infections cause significant mortality and morbidities threatening survival after ASCT, particularly in the first 1 to 3 years after the transplant.

Because of the high associated mortality rates (10%–20% within the first year post treatment) and serious adverse events, even in patients with favorable prognostic criteria (matched sibling donor, CP disease diagnosed within 1 year and <40 years of age), ASCT is considered a salvage approach after tyrosine kinase inhibitors therapy failure (Quintas-Cardama and Cortes 2006).

**Treatment with imatinib**

The introduction of imatinib represented a breakthrough for CML therapy and for the targeted approach to cancer therapy. Imatinib, a small-molecule tyrosine kinase inhibitor (TKI), was the first drug to be developed that targets Bcr-Abl (Deininger et al 2005). Imatinib binds to the inactive protein conformation, partially occluding its ATP-binding site (Schindler et al 2000). Thus imatinib prevents the switch to the active conformation of Bcr-Abl, thereby blocking signal transduction. Imatinib also inhibits other signaling proteins; for example, platelet-derived growth factor receptor and c-Kit (Buchdunger et al 2000). The efficacy of imatinib against Ph-positive CML was demonstrated in various in vitro and in vivo preclinical models (Deininger et al 2005). The clinical benefits of this drug were subsequently shown in numerous clinical trials.

The prospective International Randomized trial of Interferon plus cytarabine versus imatinib [STI-571] (IRIS) Study of 1106 patients with newly diagnosed CML in CP established the superiority of imatinib 400 mg daily over interferon-alpha and low-dose cytarabine (O’Brien et al 2003). The complete hematologic response rates were 95% versus 55%; the complete cytogenetic response rates were 76% versus 15%; and the progression-free survival rates at 18 months were 97% versus 91% (p < 0.001). The molecular response rates were also significantly better, with estimated major molecular response rates at 12 months of 40% versus 2% (O’Brien et al 2003).

A 5-year update of the IRIS study continued to show positive results (Druker et al 2006). Three hundred and eighty-two patients remained on imatinib front-line therapy.
The cumulative complete hematologic response, major cytogenetic response, and complete cytogenetic response rates were 98%, 92%, and 87%, respectively. The estimated 5-year event-free survival was 83%; only 6.3% of patients progressed to accelerated and blastic phases. The overall annual progression rate has declined to 0.9% in the fifth year of therapy, compared with 1.5%, 4.8%, and 7.5% in the previous 3 years, suggesting that disease progression may be diminished in the following years. The estimated 5-year survival rate was 89%; excluding non-CML deaths, it was 95%. The intensity of the cytogenetic response after 12 and 18 months of imatinib therapy has important implications for survival without transformation. The estimated 5-year survival rate in patients not achieving a major cytogenetic response at 12 months was significantly less (81%) than those who achieved major cytogenetic response (complete 97%, partial 93%; p < 0.001). At 18 months of therapy, the estimated 5-year survival rate for patients not achieving a complete cytogenetic response was significantly less than those who achieved complete cytogenetic response (99% versus 90%; p < 0.001). There was a continuous improvement in the rate of molecular response: the rate of major molecular response improved from 44% at 1 year to 68% at 4 years of therapy (Goldman et al 2005). This study did not document a survival advantage for imatinib because of the crossover design. Studies comparing the survival of patients treated with imatinib with historical cohorts treated with interferon-alpha-based therapy demonstrated the anticipated survival advantage (Kantarjian et al 2003; Roy et al 2006).

**Imatinib adverse events**

Adverse events (AEs) reported with imatinib are generally mild or moderate, and included superficial edema (60%), nausea (50%), muscle cramps (49%), and rashes (according to the common terminology criteria rare version 3.0). Grade 3–4 events were uncommon except for neutropenia (17%) and thrombocytopenia (9%). Only 4% of patients had to discontinue imatinib because of AEs (Druker et al 2006).

**Resistance to imatinib**

Despite the benefit of imatinib over prior treatments, some patients may develop resistance (Shah 2005), with a reported annual relapse rate of 1% to 4% in newly diagnosed patients in chronic phase with the incidence decreasing over time (Hochhaus and Hughes 2004). In fact, during the 4th and the 5th year of follow-up on the IRIS trial, less than 1% of patients have lost response per year. Multiple mechanisms of resistance to imatinib, Bcr-Abl-dependent and Bcr-Abl-independent, have been identified; one of the best characterized is mutations in the Bcr-Abl kinase domain. Mutations have been detected in 30% to 50% of patients who develop imatinib resistance (Hochhaus et al 2002). Clinically relevant mutations disrupt critical contact points between imatinib and Bcr-Abl or may favor the active conformation of Bcr-Abl, to which imatinib is unable to bind (Deininger et al 2005; Shah 2005). Numerous Bcr-Abl mutations have been identified. Not all mutations have the same biochemical and clinical properties: some Bcr-Abl mutations result in a highly resistant phenotype in vitro; others are still relatively sensitive to imatinib and resistance may potentially be overcome by a dose increase of imatinib (Corbin et al 2002; Hochhaus et al 2002; Shah et al 2002; von Bubnoff et al 2002; Azam et al 2003). The T315I mutation and some mutations affecting the so-called p-loop of Bcr-Abl confer a greater level of resistance to imatinib and to the novel tyrosine kinase inhibitors (Hughes et al 2006; Jabbour et al 2006).

Other mechanisms of imatinib resistance may include: increased expression of Bcr-Abl through genomic amplification (Nicolini et al 2006), overexpression of Lyn or other Src-family tyrosine kinases (Donato et al 2003; Dai et al 2004), or overexpression of drug efflux proteins such as P-glycoprotein, which may decrease the intracellular concentration of imatinib in leukemic cells (Thomas et al 2004). Interestingly, treatment responses correlate with plasma concentrations of imatinib, suggesting that insufficient plasma levels may contribute to imatinib resistance. In addition, clonal evolution may also be involved in imatinib resistance through inactivation of the tumor suppressor gene p53 (Wendel et al 2006). Strategies to overcome imatinib resistance are a logical progression for improving the prognosis of patients with CML.

**TKIs: The next generation**

New TKIs are available or in development that are more potent than imatinib for inhibiting Bcr-Abl and have a decreased potential for resistance. These include dasatinib (Sprycel®; BMS-354825, Bristol-Myers-Squibb), an orally bioavailable dual Bcr-Abl and Src inhibitor, and nilotinib (Tasigna®; AMN-107, Novartis), a potent selective Bcr-Abl inhibitor. Both nilotinib and dasatinib induced significant clinical responses. Dasatinib was approved for the treatment of patients with all phase CML or Ph+ ALL who are unable to tolerate or have not responded to other treatments, including imatinib. Nilotinib was approved.
for CML patients in chronic and accelerated phases, post imatinib failure. Here we review the recent available data on nilotinib.

**Nilotinib**

**Preclinical profile**

Nilotinib (formerly AMN107, Novartis Pharmaceuticals, Basel, Switzerland) is an oral TKI that was developed from its parent compound, imatinib, as a more potent inhibitor of Bcr-Abl (Golemovic et al 2005; Verstovsek et al 2005). Rational design of novel inhibitors exhibiting effectiveness against imatinib-resistant mutants of Bcr-Abl was carried out, based on the crystal structure of the imatinib-Abl complex. Crystallographic analysis has revealed that imatinib binds to and stabilizes an inactive, DFG (aspartate-phenylalanine-glycine)-out conformation of Abl in which the activation loop is in a “closed” substrate-mimicking position and there is extensive distortion of the ATP binding loop.

The high topological congruency between the anilino-pyrimidine substructure and the surface of the distorted ATP-binding pocket suggest that making changes within this region of imatinib might not be very productive. However, the methylpiperazinyl group of imatinib lies along a surface-exposed pocket of the Abl kinase and is potentially more amenable to modification. It was hypothesized that the potency and selectivity of imatinib could be improved by maintaining binding to the inactive conformation of the Abl kinase domain, but incorporating alternative binding groups to the N-methylpiperazine moiety, while preserving an amide pharmacophore to retain H-bond interactions to Glu286 and Asp381. Like imatinib, nilotinib binds to the inactive conformation of the Abl tyrosine kinase, with p-loop folding over the ATP-binding site, and the activation-loop (involving the pyridyl-N and the backbone-NH of Met318, the anilino-NH and the side-chain hydroxyl of Thr315, the amido-NH and side-chain carboxylate of Glu286, as well as the amido-C=O and backbone-NH of Asp381) blocking the substrate binding site, to disrupt the ATP-phosphate-binding site, and inhibit the catalytic activity of the enzyme (Manley et al 2005).

This better fit between nilotinib and the kinase binding site, as well as differences in interactions with specific amino acid residues, led to the development of a high-affinity ATP-competitive inhibitor, 10 to 30 times more potent than imatinib, which decreases proliferation and viability of wild-type Bcr-Abl- and imatinib-resistant Bcr-Abl mutant-expressing cells in vitro by selectively inhibiting Bcr-Abl autophosphorylation (Schindler et al 2000; Nagar et al 2002; Manley et al 2005; Weisberg et al 2005). Nilotinib inhibits the kinase activity of most Bcr-Abl mutants, except for T315I (also resistant to imatinib and dasatinib) (O’Hare et al 2005). Like imatinib, nilotinib does not inhibit Src kinase and does not bind to the inactive conformation of Bcr-Abl.

Nilotinib was tested alongside imatinib and dasatinib in 16 Bcl-Abl mutant cell lines representing >90% of clinical isolates. In recombinant kinase assays, IC₅₀ values for inhibition of substrate phosphorylation by wildtype Abl were 280, 15 and 0.6 nM for imatinib, nilotinib and dasatinib, respectively. A reduced susceptibility of >10-fold compared with wild type was seen in 7 mutants with imatinib (3 of which were completely insensitive) and 3 with nilotinib (IC₅₀ for 13/16 mutants <160 nM). The activity of dasatinib against 15 mutants remained between 0.5-fold and 1.5-fold of that against wildtype (all IC₅₀ values <1.8 nM). Inhibition of the proliferation of BaF3 cells expressing the mutant kinases followed a similar pattern for the three agents. IC₅₀ values were higher and more variable for imatinib (480–3475 nM; 3 mutants completely resistant) and nilotinib (15–450 nM) than for dasatinib (0.8–7.4 nM).

Nilotinib inhibits Abl-catalyzed peptide substrate phosphorylation with a 20-fold higher potency than imatinib [concentration of inhibitor resulting in a 50% reduction in cell viability]: 15 versus 280 nmol/L). Corresponding experiments with mutant Abl kinase domains revealed that a 20-fold improved potency of nilotinib compared with imatinib is also seen with the imatinib-resistant mutants. A model of nilotinib in complex with Abl kinase mutant M351T showed that the sensitivity of Bcr-Abl mutants to nilotinib segregates into 4 categories: high (IC₅₀ < 70 nmol/L: M244V, G250E, Q252H, F311L, F317L, M351T, V379I, L387M, H396P, H396R), medium (IC₅₀ < 200 nmol/L: Y253F, E255K, F359V), low (IC₅₀ < 450 nmol/L: Y253H, E255V), and insensitive (IC₅₀ > 2 μmol/L: T315I), with the level of nilotinib sensitivity at positions 253 and 255 dependent on the specific amino acid substitution (mutants Y253F and E255K fall in the medium classification, whereas Y253H and E255V comprise the low category). The mutants, other than T315I, that were least responsive to nilotinib in all three cellular assays were Y253H and E255V. The pattern of resistance to nilotinib and dasatinib differed; those with greatest resistance to nilotinib (Y253H and E255V) were susceptible to dasatinib. T315I remained resistant to all the three drugs.

In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment, compared with
Nilotinib in chronic myeloid leukemia


The pharmacokinetics of nilotinib have been evaluated. The median time to peak serum concentrations of nilotinib was 3 hours and the mean peak concentration at steady state, reached by day 8, in patients administered 400 mg twice daily was 3.6 μM. Nilotinib had an apparent half-life of 15 hours (Table 1). Peak concentration and area under the serum concentration-time curve at steady state increased with dose from 50 to 400 mg and plateaued with doses greater than 400 mg. Non-linearity with higher nilotinib doses is thought to result from saturation of gastrointestinal absorption; dosing nilotinib at 400 mg twice daily resulted in steady-state exposure greater than that observed with a single daily 800 mg dose. Based on these data, twice daily dosing was selected for phase II studies of nilotinib.

The treatment was well tolerated. At the dose of 400 mg twice daily, grade 3 or 4 nonhematologic adverse events included pruritus (3%), increased total and conjugated (3%) as well as unconjugated bilirubin levels (3%), increased lipase levels (9%), and increased levels of liver enzymes (3%). Most frequent grade 3–4 adverse events were hematologic: the incidence of grade 3 or 4 thrombocytopenia
was 25%, and the incidences of grade 3 or 4 anemia and neutropenia were less than 10%. Other adverse events were less frequent and were primarily grade 1–2. In this study, nilotinib was not associated with the edema frequently associated with imatinib.

Neutropenia and indirect self-limited reversible hyperbilirubinemia were observed mostly at the dose of 600 mg twice daily. A nilotinib dose of 400 mg twice daily was selected for the phase 2 studies based on efficacy and long-term side effects.

**Phase 2 clinical trials**

Consistent with phase 1 results, results from following phase 2 studies have demonstrated activity in all phases of disease. Thus, nilotinib has been approved in both the US and Europe for the treatment of patients with CML-CP and -AP who are resistant or intolerant to prior therapy, including imatinib. Three single-arm studies in patients with all phases of imatinib-resistant or imatinib-intolerant CML or Ph-positive ALL were recently updated (Ottmann et al 2007; Giles et al 2008; Kantarjian et al 2008; le Coutre et al 2008) (Table 2).

Intolerance was defined as any non-hematologic toxicity of grade 3 or higher severity, or of grade 2 or higher severity lasting more than 1 month or recurring more than 3 times despite dose reduction and maximal supportive care.

The definition of intolerance also included hematologic toxicity of grade 4 severity persisting for more than 7 days. Imatinib-intolerant patients who had previously demonstrated sensitivity to imatinib, as evidenced by a prior major cytogenetic response, were to be excluded from participation in the studies.

At the time of the report, 321 patients (71% imatinib-resistant; 21% imatinib-intolerant) with CML-CP treated with nilotinib were evaluable (Kantarjian et al 2008). Nilotinib was started at 400 mg twice daily (bid), on an empty stomach, and escalated to 600 mg bid for inadequate responses. Complete hematologic response was reported in 158 of 206 patients with active disease at the beginning (77%). Overall, the major cytogenetic response rate was 57%; 41% had a complete cytogenetic response. Major cytogenetic responses were observed in 125 (55%) of the 227 imatinib-resistant patients and in 59 (63%) of the 94 imatinib-intolerant patients. The median time to complete hematologic response and major cytogenetic response was 1.0 and 2.8 months, respectively. The majority of patients (84%) maintained the major cytogenetic response for at least 18 months. At 18 months, the estimated overall survival rate was 91%.

One hundred and thirty-six patients with CML-AP received at least 1 dose of nilotinib, with a median treatment duration of 210 days (le Coutre et al 2008). A confirmed hematologic response occurred in 69/129 patients (54%); 26% had a complete hematologic response. Major cytogenetic responses occurred in 40/129 patients (31%); 24/129 patients (19%) had complete cytogenetic responses. Thirty out of 104 patients (29%) of imatinib-resistant patients and 10/25 imatinib-intolerant patients (40%), had a major cytogenetic response. Time to first hematologic response and major cytogenetic response was 1 and 2.8 months, respectively. At 12 months, it was estimated that 57% of patients were without progression and the estimated overall survival rate was 81%.

One hundred and thirty-six patients with CML-BP (myeloid, n = 105; lymphoid, n = 31) were treated with nilotinib 400 mg twice daily (Giles et al 2008). The hematologic response rate was 21% and 11% achieved complete hematologic response. Major cytogenetic response was achieved in 55 patients (40%), and 40 (29%) had complete cytogenetic response. Overall survival at 12 months was 42%. Treatment with nilotinib is ongoing in 13 patients (10%). More than half of patients discontinued treatment due to disease progression.

In all three studies, nilotinib was well tolerated. The toxicity profile was consistent with the phase 1 study.

### Table 1

<table>
<thead>
<tr>
<th>Disease</th>
<th>N</th>
<th>% Response</th>
<th>Cytogenetic response</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>CML chronic</td>
<td>321</td>
<td>77</td>
<td>57</td>
<td>41</td>
</tr>
<tr>
<td>CML accelerated</td>
<td>136</td>
<td>26</td>
<td>31</td>
<td>19</td>
</tr>
<tr>
<td>CML blastic</td>
<td>136</td>
<td>11</td>
<td>40</td>
<td>29</td>
</tr>
</tbody>
</table>

**Abbreviations:** CHR, complete hematologic response; CML, chronic myeloid leukemia; ALL, acute lymphoid leukemia; Ph, Philadelphia chromosome.

### Table 2

<table>
<thead>
<tr>
<th>Route and formulation</th>
<th>Oral: 200 mg caps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>T&lt;sub&gt;max&lt;/sub&gt; 3 hours</td>
</tr>
<tr>
<td>Plasma half-life</td>
<td>15–17 hours</td>
</tr>
<tr>
<td>Metabolism</td>
<td>By CYP 3A4, through oxidation and hydroxilation</td>
</tr>
<tr>
<td>Excretion</td>
<td>Mostly in feces</td>
</tr>
</tbody>
</table>

The toxicity profile was consistent with the phase 1 study.
with generally low and manageable rates of severe adverse events. The rate of grade 3–4 neutropenia was 30% in CP, 39% in AP, and 67% in BP. The rate of grade 3–4 thrombocytopenia was 28% in CP, 41% in AP, and 62% in BP. Non-hematologic side effects were infrequent and were usually grade 1–2. These included fatigue, pruritus, headache, muscle spasms, and gastrointestinal disturbances. Grade 3–4 non-hematologic adverse events were rare and included rash, headache, diarrhea, nausea, and fatigue. Transient self-limited elevations of indirect bilirubin were noted. One patient had sudden cardiac death. A low incidence of QT prolongation (QTcF >500 msec, <1%) was observed overall.

These reports suggest that nilotinib may provide a safe and effective treatment option for CML. There was minimal cross intolerance between imatinib and nilotinib (Jabbour et al 2008). Nilotinib was associated with less fluid retention, edema, cramps, and weight gain, or with pleural effusions.

**Front-line therapy**

As seen with imatinib resistance in CML, cancer cells have the capacity to mutate and acquire properties that enable them to develop resistance to treatment. As a significant proportion of patients are/become resistant to imatinib, earlier use of nilotinib (ie, as a front-line therapy) in all phases of CML may be beneficial in 2 potential ways: by promoting an early response, thereby potentially improving prognosis; and/or by avoiding the development of treatment resistance. The clinical challenge in this setting would be to accurately identify patients who are likely to fail imatinib treatment by using clinical risk factors and genetic testing as predictive factors.

A phase 2 study in patients with newly diagnosed CML-CP showed that nilotinib 400 mg twice daily induces a complete cytogenetic response in nearly all patients as early as 3 months after the start of therapy with a favorable toxicity profile. Thirty-five patients have been treated for a median of 6.5 months. Complete cytogenetic responses were achieved, respectively, by 96% and by 100% of patients at 3- and 6-month evaluations. The rate of complete cytogenetic response at 3, 6 and 12 months compares favorably to those observed in historical controls treated with imatinib 400 mg or 800 mg daily: at 12 months 100% of patients were still in response. Major molecular response was observed in 13% at 3 months, 45% at 6 months and 45% at 12 months. Nilotinib showed generally low and manageable rates of grades 3–4 adverse events (Cortes et al 2008).

**Potential resistance to second generation TKIs**

As clinical experience with second generation TKIs grows, it is becoming clear that patients can also relapse on treatment after an initial response, particularly in the setting of advanced-phase CML. Although over expression of Bcr-Abl is a possible resistance mechanism for nilotinib (Mahon et al 2004), resistance is more likely to arise through the emergence of clones expressing nilotinib-resistant mutant forms of Bcr-Abl. With the increased use of these newer TKIs, it has been suggested that the spectrum of kinase domain mutations may change. As these compounds enter the clinical arena, it would be useful to predict the profile of mutations that confer drug resistance because this would allow for a rational approach to the design of combination strategies. Experimental models of in vitro drug sensitivity exposing Bcr-Abl-expressing cells to nilotinib or dasatinib under conditions that favor the development of mutations have shown that although their mutagenic potential is lower than that of imatinib, mutations may still emerge (Table 3).

<table>
<thead>
<tr>
<th>Table 3 In vitro mutagenesis for resistance to nilotinib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Von Bubnoff et al</strong></td>
</tr>
<tr>
<td>K247N</td>
</tr>
<tr>
<td>Q252H</td>
</tr>
<tr>
<td>Y253H</td>
</tr>
<tr>
<td>E255V</td>
</tr>
<tr>
<td>E255V</td>
</tr>
<tr>
<td>E255K</td>
</tr>
<tr>
<td>E292V</td>
</tr>
<tr>
<td>F311I</td>
</tr>
<tr>
<td>T315I</td>
</tr>
<tr>
<td>F359I</td>
</tr>
<tr>
<td>F359V</td>
</tr>
<tr>
<td>L387F</td>
</tr>
</tbody>
</table>
In a cell-line-based mutagenesis study, the emergence of Bcr-Abl mutations resistant to imatinib, nilotinib and dasatinib were compared: 20 different mutations were identified with imatinib mesylate, 10 with nilotinib (including only 1 novel mutation, E292V) and 9 with dasatinib. In contrast to imatinib mesylate, mutations recovered in the presence of 50 nM nilotinib were limited to L248V, G250E, Y253H, E255K (p-loop), T315I, F359C, L384M and L387F. One novel mutation (E292V) was seen in a single clone at 50 nM. At 500 nM, only Y253H, E255V and T315I were detected, in line with their reported level of resistance in cell proliferation assays. At concentrations of at least 2000 nM, only T315I was recovered. The fact that only 1 novel mutation occurred at a low concentration and the lack of novel, previously undescribed mutations at intermediate inhibitor concentrations (500 nM) suggests that the structural modifications of nilotinib compared with imatinib do not generate clinically relevant novel vulnerable sites. Because the plasma trough concentrations at the maximum tolerated dose (MTD) of nilotinib (400 mg twice daily) are in the range of 2000 nM, the prediction is that only T315I will emerge in patients treated with the MTD. Interestingly, with combination of nilotinib plus other TKIs such as imatinib or dasatinib, maximal suppression of resistant clone outgrowth was achieved with lower concentrations compared with single agents (Bradeen et al 2006).

An alternative cell-based screening assay designed to predict such mutations has recently been applied to nilotinib (von Bubnoff et al 2006). Using this system, a reduced pattern of mutations was observed for nilotinib, having some overlap with that seen for imatinib: Q252H, Y253H, E255K(V), F311I, T315I, S349L and F359I(V), all of which, with the exception of the T315I mutant, were suppressed at clinically achievable concentrations of nilotinib. Bcr-Abl point mutations conferring resistance to nilotinib have also been identified in a random mutagenesis study (Ray et al 2005). In this study, 11 novel mutations were detected (K247N, L248V, L273F, E282K, K285N, V289L, E292K, N297T, H375P, T406I and W430L), in addition to 5 (Q252H, Y253C (H), E255K and T315I), which have been previously observed in CML patients treated with imatinib. Although these studies do not consistently identify the same drug-resistant Bcr-Abl point mutations for individual drugs, it is clear that all 3 compounds display different mutagenic profiles.

The patterns of mutations occurring in patients with all phase CML treated sequentially with imatinib, and 1 or 2 second-generation TKIs after imatinib failure were investigated (Cortes et al 2007). Response rates were similar for patients with and without mutations, regardless of mutation site except for T315I. Acquisition of kinase domain mutations was the most frequently identified mechanism of resistance for patients who failed a second-generation TKI therapy. The codons involved were diverse, and most frequently included those also seen after imatinib failure. However, some mutations occurred more frequently after specific second TKIs, such as F317L after dasatinib, and certain p-loop mutations after nilotinib. Few novel mutations also emerged, such as V299L after dasatinib, and in some instances they did not confer resistance to imatinib. An increase in the frequency of T315I was not observed. The spectrum of mutations that emerged following therapy with second TKIs was compared to those that developed in previously published in vitro mutagenesis models. The mutations that persisted or developed following switch to new TKI were at sites also found in prior in vitro TKI mutagenesis assays.

Mutation regression/acquisition/persistence generally reflected the in vitro differential sensitivity predicted for each TKI. The mutations emerging after nilotinib and dasatinib also correlate to some extent with those that had the least in vitro sensitivity to these agents.

Preliminary analysis from phase 2 studies suggested that levels of response to new TKIs depend on the type of Bcr-Abl kinase domain mutation. Specifically, patients harboring native Bcr-Abl and patients with a sensitive mutation had comparable response rates, whereas patients with mutations that confer intermediate sensitivity in vitro exhibited lower rates of major cytogenetic response. The clinical response of BCR-ABL with particular mutations has been modeled by classifying each mutation based on the in vitro IC<sub>50</sub> for each drug against kinase activity for Bcr-Abl with that mutation into high-, intermediate- and low-sensitivity groups. Mutation sensitivity was defined by the IC<sub>50</sub> value: IC<sub>50</sub> values were <3 , <60 and >60 nM for dasatinib, and <50, <500 and >500 nM for nilotinib (O’Hare et al 2007a) (Table 4). Investigating whether in vitro sensitivity of kinase domain mutation correlates with outcome of patients receiving second generation TKI, it was found that the outcome depends on the type of mutation, with mutations with predicted intermediate levels of sensitivity having decreased probability of response and event free survival, particularly in CP. The correlation with IC<sub>50</sub> was less evident in advanced phases suggesting more complex mechanisms of resistance. In the same line, overall survival of patients with T315I mutations was mostly found to be
dependent on the stage of the disease (Jabbour et al 2007a). If this preliminary observation holds, rational decisions on drug and dose may require consideration of mutation type. In patients failing a TKI in whom a mutation with intermediate in vitro sensitivity to this agent is detected, change to an agent with better in vitro potency against such mutation may improve the response (Jabbour et al 2007b). The setting for outgrowth of different mutations and their subsequent response to different TKIs varies significantly. For example, mutations in codon 317, which impairs dasatinib binding, have been generated during in vitro mutagenesis with dasatinib but not nilotinib, and the F317L, in particular, has been reported following treatment with dasatinib. TKIs showing differential in vitro activity against this mutation, like nilotinib, may represent the best option for F317L-mutated tumors (Jabbour et al 2007c).

### Combination therapy

There is growing interest in testing the hypothesis that administration of multiple Abl kinase inhibitors in early-phase patients, could be used to delay or prevent the emergence of drug-resistant clones (Shah et al 2005). The combination of 2 agents targeting different pathways involved in CML may significantly improve response rates and potentially increase survival.

Support for this concept is provided by preliminary preclinical investigations of the imatinib–nilotinib combination (Weisberg et al 2007). Additive/synergistic toxicity against both imatinib-sensitive and imatinib-resistant Bcr-Abl-expressing cells has been reported following coadministration of nilotinib and imatinib, in vitro and in vivo (Griffin and Weisberg 2005; Weisberg et al 2005; Weisberg et al 2007).

This cooperative activity could result from pharmacodynamic interactions with cell transporters. Preliminary data suggest that synergy between imatinib and nilotinib may occur at the level of the CML stem cell due to the ability of both imatinib and nilotinib to inhibit or act as substrates of the multidrug efflux transporter Abcg2, which confers resistance toward several anticancer drugs (Brendel et al 2007). It is also reported that imatinib and nilotinib might be taken up in cells by different mechanisms, with the influx, intracellular concentrations of imatinib, and consequently patient sensitivity to imatinib depending upon the organic cation transporter Oct-1, whereas nilotinib transport appears to be independent of Oct-1 (White et al 2006).

Both nilotinib and dasatinib efficiently block Bcr-Abl tyrosine kinase catalytic activity by binding to distinct, partially overlapping sites in the kinase domain. Cross-resistance with dasatinib is limited to T315I, which is also the only mutant isolated at drug concentrations equivalent to maximal achievable plasma trough levels (O’Hare et al 2005). With drug combinations maximal suppression of resistant clone outgrowth was achieved at lower concentrations compared with single agents, suggesting that such combinations may be equipotent to higher dose single agents. A combination of low doses of dasatinib and low doses of nilotinib may effectively suppress the emergence of mutations other than T315I with an acceptable safety profile (Talpaz et al 2006; Jabbour et al 2007d). This approach needs to be eventually extended to include specific inhibitors of T315I Bcr-Abl kinase domain mutations. Alternatively, it is also important to explore the potential for synergy between nilotinib and other classes of inhibitors that work through mechanisms not involving inhibition of Abl tyrosine kinase activity (Fiskus et al 2006; O’Hare et al 2007b; O’Hare et al 2008).

### Conclusion

The development of imatinib and subsequent studies into mechanisms of imatinib resistance have intensified the development of additional treatments for CML. Targeted agents have significantly improved the prognosis in CML. Further optimization of treatment responses may require patient-specific therapy based on an evaluation of disease characteristics.

### Disclosures

EJ is on the speakers bureau of Novartis and Bristol-Myers-Squibb. HK and JC have received grants from Novartis and Bristol-Myers-Squibb.

### References


